Email updates

Keep up to date with the latest news and content from Breast Cancer Research and BioMed Central.

Highly Accessed Viewpoint

Adjuvant treatment of HER2-positive breast cancer: winning efforts continue to improve HER2-positive patient outcome long-term

Rachel C Jankowitz and Adam M Brufsky*

Author Affiliations

University of Pittsburgh Cancer Institute, Magee-Women's Hospital, 300 Halket Street, Suite 4628, Pittsburgh, PA 15213, USA

For all author emails, please log on.

Breast Cancer Research 2012, 14:308  doi:10.1186/bcr3120

Published: 30 April 2012

Abstract

Randomized adjuvant trials continue to show significant reductions in distant recurrence and death for early-stage women treated with adjuvant trastuzumab. BCIRG-006 showed superior disease-free and overall survival of two trastuzumab-containing regimens in comparison to a non-trastuzumab-containing regimen. The rates of disease-free and overall survival were not statistically different for the two trastuzumab-containing arms. Ongoing study is needed to identify markers of resistance to trastuzumab and incorporate newer agents in the adjuvant setting in order to further decrease rates of distant recurrence and death from HER2-positive breast cancer.